NEW INDICATIONS

Tecentriq First Immunotherapy FDA Approved for Adjuvant Treatment of Early-Stage Non–Small-Cell Lung Cancer

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On October 15, 2021, the FDA accelerated the approval of a new indication for atezolizumab (Tecentriq; Genentech), for the adjuvant treatment, after resection and platinum-based chemotherapy, of patients with stage II-IIIA non–small-cell lung cancer (NSCLC) and PD-L1 expression ≥1%, as determined by an FDA-approved test.

Atezolizumab is the first immunotherapy to receive FDA approval for the adjuvant treatment of early-stage (stage II-IIIA) NSCLC. This approval was based on recent results from the phase 3 IMpower010 clinical trial.

Simultaneously, the FDA also approved the VENTANA PD-L1 Assay (Ventana Medical Systems) as a companion diagnostic test to identify appropriate patients with NSCLC for adjuvant treatment with atezolizumab.

“Too many patients with early-stage lung cancer experience disease recurrence following surgery. Now, the availability of immunotherapy following surgery and chemotherapy offers many patients new hope and a powerful new tool to reduce their risk of cancer relapse,” said Bonnie Addario, Co-Founder and Chair, GO2 Foundation for Lung Cancer. “With this approval, it is more important than ever to screen for lung cancer early and test for PD-L1 at diagnosis to help bring this advance to the people who can benefit.”

The major efficacy outcome was disease-free survival (DFS), as assessed by the investigator in the primary efficacy analysis population. The study included 476 patients with stage II-IIIA NSCLC and PD-L1 expression ≥1% who received atezolizumab or best supportive care.

The median DFS was not reached (95% confidence interval [CI], 36.1-not estimable [NE]) in the atezolizumab arm versus 35.3 months (95% CI, 29.0-NE) in patients in the best supportive care arm (hazard ratio, 0.66; 95% CI, 0.50-0.88; P = .004).

In a prespecified secondary subgroup analysis of patients with stage II-IIIA NSCLC and PD-L1 expression ≥50%, the hazard ratio for DFS was 0.43 (95% CI, 0.27- 0.68). And in an exploratory subgroup analysis of patients with stage II-IIIA NSCLC and PD-L1 expression of 1% to 49%, the hazard ratio for DFS was 0.87 (95% CI, 0.60-1.26).

The most common (≥10%) adverse reactions (including laboratory abnormalities) with atezolizumab in this study were increased aspartate aminotransferase, blood creatinine, and alanine aminotransferase; hyperkalemia, rash, cough, hypothyroidism, pyrexia, fatigue/asthenia, musculoskeletal pain, peripheral neuropathy, arthralgia, and pruritus.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: